214 related articles for article (PubMed ID: 27706216)
1. Clinical and Economic Impact of a Digital, Remotely-Delivered Intensive Behavioral Counseling Program on Medicare Beneficiaries at Risk for Diabetes and Cardiovascular Disease.
Chen F; Su W; Becker SH; Payne M; Castro Sweet CM; Peters AL; Dall TM
PLoS One; 2016; 11(10):e0163627. PubMed ID: 27706216
[TBL] [Abstract][Full Text] [Related]
2. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
3. A coordinated national model for diabetes prevention: linking health systems to an evidence-based community program.
Vojta D; Koehler TB; Longjohn M; Lever JA; Caputo NF
Am J Prev Med; 2013 Apr; 44(4 Suppl 4):S301-6. PubMed ID: 23498291
[TBL] [Abstract][Full Text] [Related]
4. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
[TBL] [Abstract][Full Text] [Related]
5. The estimated costs and savings of medical nutrition therapy: the Medicare population.
Sheils JF; Rubin R; Stapleton DC
J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
[TBL] [Abstract][Full Text] [Related]
6. Return on Investment for Digital Behavioral Counseling in Patients With Prediabetes and Cardiovascular Disease.
Su W; Chen F; Dall TM; Iacobucci W; Perreault L
Prev Chronic Dis; 2016 Jan; 13():E13. PubMed ID: 26820045
[TBL] [Abstract][Full Text] [Related]
7. New Medicare Diabetes Prevention Coverage May Limit Beneficiary Access and Widen Health Disparities.
Ritchie ND; Gritz RM
Med Care; 2018 Nov; 56(11):908-911. PubMed ID: 30312286
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
[TBL] [Abstract][Full Text] [Related]
9. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
10. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
[TBL] [Abstract][Full Text] [Related]
11. Medicare's intensive behavioral therapy for obesity: an exploratory cost-effectiveness analysis.
Hoerger TJ; Crouse WL; Zhuo X; Gregg EW; Albright AL; Zhang P
Am J Prev Med; 2015 Apr; 48(4):419-25. PubMed ID: 25703178
[TBL] [Abstract][Full Text] [Related]
12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
13. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.
Anderson JM
J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis.
Mudaliar U; Zabetian A; Goodman M; Echouffo-Tcheugui JB; Albright AL; Gregg EW; Ali MK
PLoS Med; 2016 Jul; 13(7):e1002095. PubMed ID: 27459705
[TBL] [Abstract][Full Text] [Related]
16. Estimation and Prediction of Avoidable Health Care Costs of Cardiovascular Diseases and Type 2 Diabetes Through Adequate Dairy Food Consumption: A Systematic Review and Micro Simulation Modeling Study.
Javanbakht M; Jamshidi AR; Baradaran HR; Mohammadi Z; Mashayekhi A; Shokraneh F; Rezai Hamami M; Yazdani Bakhsh R; Shabaninejad H; Delavari S; Tehrani A
Arch Iran Med; 2018 May; 21(5):213-222. PubMed ID: 29738265
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of a Web-based diabetes prevention program: 2-year results of a single-arm longitudinal study.
Sepah SC; Jiang L; Peters AL
J Med Internet Res; 2015 Apr; 17(4):e92. PubMed ID: 25863515
[TBL] [Abstract][Full Text] [Related]
18. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
